MDMA-assisted Therapy Market

MDMA-assisted Therapy Market - Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031

PUNE, MAHARASHTRA, INDIA, May 6, 2022 /EINPresswire.com/ -- The healthcare vertical is seeing an influx of self-moving smart devices, which ought to extend support to the medical staff by curtailing their supply management or sanitation-related chores. Smart helpers could be used for remote monitoring of oxygen saturation and blood pressure levels for the patients, as they are of utmost importance regarding their health condition. This would be the scenario with MDMA-assisted Therapy Market in the subsequent decade.

According to the latest research by Persistence Market Research, the MDMA-assisted therapy market is set to witness positive growth of CAGR 3.4% during 2021-2031. MDMA (3-4 methylenedioxymethamphetamine) is a drug that can be used in posttraumatic stress disorder (PTSD), the anxiety caused due to end-stage diseases like cancer.

PTSD can occur after any traumatic event or can occur with depression and anxiety. The MDMA- assisted therapy market is mainly driven by the increase in the prevalence of PTSD, anxiety, new products in the pipeline and government initiatives for treatment of PTSD. The companies are exploring treatment options for PTSD with the help of derivatives of MDMA and different combinations.

To remain ‘ahead’ of your competitors, request for a sample@ https://www.persistencemarketresearch.com/samples/32977

MDMA- assisted therapy includes treatment of posttraumatic stress disorder, anxiety related to end-stage diseases like cancer, social anxiety in autistic patients, etc. According to the national centre for PTSD, about 6% of the population will have PTSD at some point in their lives. Also, in the U.S. during a given year about 15 million people suffer from PTSD. This increasing prevalence of PTSD will drive the market in the forecasted period.

The initiatives taken by the government for the awareness of anxiety and post-trauma stress will drive the market. For instance, the U.S. is the helpline centre for veterans who are diagnosed with PTSD or suffer from the same. In addition, the firms are working on clinical trials for using MDMA as a medication to treat PTSD.

Moreover, an increase in the awareness about MDMA-assisted therapy and R & D investment by the companies for developing new products is expected to increase demand for MDMA-assisted therapy during the forecast period.

Currently, there are no FDA approved MDMA drugs available in the market. However, the companies are involved in clinical trials for the treatment of post-traumatic stress disorder (PTSD), anxiety related to cancer, depression etc. For instance, in 2019, Atai Life Sciences and Bionomics partnered together for exploring the combination treatment regimen.

For the entire list of market players, request for Table of Content here @ https://www.persistencemarketresearch.com/toc/32977

This combination included EmpathBio’s MDMA derivative, EMP-01, and Bionomics’ lead drug candidate, BNC210. Apart from this, in June 2021, Awakn Life Sciences Corp. has filed a patent application for its MDMA-derived new chemical entities, AWKN001 and AWKN002 for the treatment of a broad range of addictions.

The MDMA –assisted therapy market is mainly dominated by North America with countries like the US and Canada is dominating the MDMA-assisted therapy market. This is due to the presence of major players like Awakn Life Sciences and the government initiatives to spread awareness about post-trauma stress.

Another region that is expected to dominate the market is Europe followed by Asia. This is because PTSD is common in this area. According to a study published in Oxford Medicine, PTSD affects approximately 1% to 3% of the European population every year.

Pre-Book Right Now for Exclusive Analyst Support@ https://www.persistencemarketresearch.com/checkout/32977

Access Related Reports-

Non-Melanoma Skin Cancer Market
The global non-melanoma skin cancer treatment market is anticipated to be valued at revenue of more than US$ 705 Mn at the end of the forecast period from 2017-2025.

Hepatitis C Treatment Market
The global hepatitis C treatment market is projected to be valued at US$ 23.9 Bn by the end of 2015 and is further expected to reach US$ 71.13 Bn by 2024 end, registering a CAGR of 13.1%.

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

Atul Singh
PMR
+1 646-568-7751
email us here
Visit us on social media:
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.